PLOD2 and neoplasm: In the Hannover cohort, GBM patients with high tumor levels of PLOD2 (PLOD2high) had a significantly shorter OS compared to patients with low levels of PLOD2 (PLOD2low) (p = 0.020; log-rank) (Figure 1A).